Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model.
Lessons from the adjuvant bevacizumab trial on colon cancer: what next?
J Clin Oncol. 2011;29(1):1-4 - PMID: 21115866 - DOI: 10.1200/JCO.2010.32.2701
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas.
Int J Radiat Oncol Biol Phys. 2011;81(4):1081-90 - PMID: 20932656 - PMCID: PMC3021107 - DOI: 10.1016/j.ijrobp.2010.07.024
Delivering nanomedicine to solid tumors.
Nat Rev Clin Oncol. 2010;7(11):653-64 - PMID: 20838415 - PMCID: PMC3065247 - DOI: 10.1038/nrclinonc.2010.139
Notch leads lymphatics and links them to blood vessels.
Arterioscler Thromb Vasc Biol. 2010;30(9):1682-3 - PMID: 20720193 - PMCID: PMC2945915 - DOI: 10.1161/ATVBAHA.110.210633
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(8):845-51 - PMID: 20667969 - PMCID: PMC3078712 - DOI: 10.1634/theoncologist.2010-0030
Premetastatic lung niche: is vascular endothelial growth factor receptor 1 activation required?
Cancer Res. 2010;70(14):5670-3 - PMID: 20587530 - PMCID: PMC2919170 - DOI: 10.1158/0008-5472.CAN-10-0119
Lymphotoxin-alpha contributes to lymphangiogenesis.
Blood. 2010;116(12):2173-82 - PMID: 20566898 - PMCID: PMC2951858 - DOI: 10.1182/blood-2009-12-256065
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(6):577-83 - PMID: 20484123 - PMCID: PMC3061828 - DOI: 10.1634/theoncologist.2010-0029
In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor model.
p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis.
Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?
J Clin Oncol. 2010;28(2):183-5 - PMID: 19949009 - DOI: 10.1200/JCO.2009.24.8021
Determinants of leukocyte margination in rectangular microchannels.
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo.
Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast.
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Cancer Res. 2009;69(13):5296-300 - PMID: 19549889 - PMCID: PMC2824172 - DOI: 10.1158/0008-5472.CAN-09-0814
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials.
Int J Radiat Oncol Biol Phys. 2009;74(5):1580-91 - PMID: 19540073 - DOI: 10.1016/j.ijrobp.2009.03.047
A new target for tumor therapy.
N Engl J Med. 2009;360(25):2669-71 - PMID: 19535806 - PMCID: PMC4792114 - DOI: 10.1056/NEJMcibr0902054
Biomarkers of response and resistance to antiangiogenic therapy.
Nat Rev Clin Oncol. 2009;6(6):327-38 - PMID: 19483739 - PMCID: PMC3057433 - DOI: 10.1038/nrclinonc.2009.63
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
J Clin Oncol. 2009;27(18):3020-6 - PMID: 19470921 - PMCID: PMC2702234 - DOI: 10.1200/JCO.2008.21.1771
PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment.
Anti-vascular endothelial growth factor therapy for malignant glioma.
Curr Neurol Neurosci Rep. 2009;9(3):254-62 - PMID: 19348715 - PMCID: PMC4790123 - DOI: 10.1007/s11910-009-0037-2
Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells.
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
J Clin Oncol. 2009;27(15):2542-52 - PMID: 19332720 - PMCID: PMC2739611 - DOI: 10.1200/JCO.2008.19.9356
Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis.
Cancer Res. 2009;69(7):2801-8 - PMID: 19318557 - PMCID: PMC2670480 - DOI: 10.1158/0008-5472.CAN-08-4051
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Neuro Oncol. 2009;11(6):853-60 - PMID: 19293394 - PMCID: PMC2802405 - DOI: 10.1215/15228517-2009-010
Visualizing anti-tumor immune responses in vivo.
Micro-environmental mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells.
Lack of lymphatic vessel phenotype in LYVE-1/CD44 double knockout mice.
Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.
Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization.
Nat Clin Pract Cardiovasc Med. 2007;4(9):491-502 - PMID: 17712362 - DOI: 10.1038/ncpcardio0979
Angiogenesis in brain tumours.
Nat Rev Neurosci. 2007;8(8):610-22 - PMID: 17643088 - DOI: 10.1038/nrn2175
American Association for Cancer Research 98th Annual Meeting. Angiogenesis and anti-angiogenesis in cancer.
IDrugs. 2007;10(6):366-9 - PMID: 17641996
Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.
Microvasc Res. 2007;74(2-3):72-84 - PMID: 17560615 - PMCID: PMC2100036 - DOI: 10.1016/j.mvr.2007.05.003
Influence of tumor cell and stroma sensitivity on tumor response to radiation.
Cancer Res. 2007;67(9):4016-21 - PMID: 17483312 - DOI: 10.1158/0008-5472.CAN-06-4498
Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed?
Lancet Oncol. 2007;8(5):444-8 - PMID: 17466902 - PMCID: PMC2712886 - DOI: 10.1016/S1470-2045(07)70140-7
A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.
Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.
Cancer Res. 2007;67(6):2729-35 - PMID: 17363594 - PMCID: PMC3022341 - DOI: 10.1158/0008-5472.CAN-06-4102
Robust 3-D modeling of vasculature imagery using superellipsoids.
IEEE Trans Med Imaging. 2007;26(2):223-37 - PMID: 17304736 - DOI: 10.1109/TMI.2006.889722
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize.
J Cell Biochem. 2007;101(4):937-49 - PMID: 17171643 - DOI: 10.1002/jcb.21187
Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice.
Semin Oncol. 2006;33(5 Suppl 10):S35-40 - PMID: 17145523 - PMCID: PMC2686124 - DOI: 10.1053/j.seminoncol.2006.08.007
Platelet-derived growth factor receptor-beta in Gorham's disease.
Nat Clin Pract Oncol. 2006;3(12):693-7 - PMID: 17139320 - PMCID: PMC2693369 - DOI: 10.1038/ncponc0660
Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications.
Cancer Res. 2006;66(16):8065-75 - PMID: 16912183 - DOI: 10.1158/0008-5472.CAN-06-1392
Evolution of oxygen and glucose concentration profiles in a tissue-mimetic culture system of embryonic stem cells.
Ann Biomed Eng. 2006;34(8):1247-58 - PMID: 16832606 - DOI: 10.1007/s10439-006-9134-4
The role of nitric oxide in tumour progression.
Nat Rev Cancer. 2006;6(7):521-34 - PMID: 16794635 - DOI: 10.1038/nrc1910
Molecular mechanisms of metastasis.
Cancer Metastasis Rev. 2006;25(2):203-20 - PMID: 16770533 - DOI: 10.1007/s10555-006-8500-x
A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles.
J Appl Physiol. 2006;101(4):1162-9 - PMID: 16763103 - DOI: 10.1152/japplphysiol.00389.2006
Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models.
Cancer Res. 2006;66(8):3971-7 - PMID: 16618713 - DOI: 10.1158/0008-5472.CAN-04-3085
783